Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sulfadoxine-Pyrimethamine/Chloroquine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Azithromycin/Chloroquine | DRUG | - |
| Sulfadoxine-Pyrimethamine/Chloroquine | DRUG | - |
INCLUSION CRITERIA: * Females and males \>=18 years of age with uncomplicated, symptomatic malaria as indicated by the presence of both of the following: a.) Blood smears positive for Plasmodium falciparum asexual parasitemia between 1000 -100,000 parasites/uL; b.) Fever or history of fever ( \>=38...
Sulfadoxine-Pyrimethamine/Chloroquine is used for the treatment of uncomplicated Plasmodium falciparum malaria. It is a combination of sulfadoxine, pyrimethamine, and chloroquine, which are antimalarial drugs. The combination is being studied for its efficacy in treating this type of malaria infection.
Sulfadoxine-Pyrimethamine/Chloroquine is being developed by Pfizer, Inc., a company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research to evaluate the safety and efficacy of this drug combination for the treatment of malaria.
Sulfadoxine-Pyrimethamine/Chloroquine is in Phase 2 clinical development. It is an investigational drug combination and has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug is still in the clinical development process.
Sulfadoxine-Pyrimethamine/Chloroquine has been studied in one completed Phase 2 clinical trial with the identifier NCT00074841. The trial enrolled 230 participants in India and evaluated the combination for the treatment of uncomplicated Plasmodium falciparum malaria in adults aged 18 years and older.
Sulfadoxine-Pyrimethamine/Chloroquine is a combination drug that includes chloroquine along with sulfadoxine and pyrimethamine. It is not the same as chloroquine alone, as it contains additional antimalarial agents. The combination is being studied to potentially improve treatment outcomes for malaria.